Identifying real differences in live birth rates between HMG and rFSH in IVF

Reproductive BioMedicine Online

Volumn 18, Issue SUPPL. 2, 2009, Pages

  Afnan, Masoud ^a  

^a BIRMINGHAM WOMEN S HOSPITAL   (United Kingdom)

Author keywords

HCG; HMG; IVF; LH activity; Ovarian stimulation

Indexed keywords

CHORIONIC GONADOTROPIN; FOLLITROPIN; GONADORELIN AGONIST; HUMAN MENOPAUSAL GONADOTROPIN; LUTEINIZING HORMONE; RECOMBINANT FOLLITROPIN;

ARTICLE; BIRTH RATE; CLINICAL TRIAL; DELIVERY; DRUG EFFICACY; FERTILIZATION IN VITRO; HORMONE ACTION; HUMAN; INFERTILITY THERAPY; INTRACYTOPLASMIC SPERM INJECTION; LIVE BIRTH; OVULATION INDUCTION; PREGNANCY OUTCOME; PREGNANCY RATE;

EID: 64949192183     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-6483(10)60445-2     Document Type: Article

References (36)

1. Afnan M, Coomarasamy A, van Wely M et al. 2007 Statistically significant increase in live births with hMG in IVF and ICSI cycles versus rFSH: results from a systematic review. Human Reproduction 22, i39.
2. Al-Inany HG, Abou-Setta AM, Aboulghar MA, Serour GI 2008 Efficacy and safety of human menopausal gonadotrophins versus recombinant FSH: a meta-analysis. Reproductive BioMedicine Online 16, 81-88.
3. Andersen AN, Devroey P, Arce JC 2006 Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial. Human Reproduction 21, 3217-3227.
4. Andersen CY, Westergaard LG, van Wely M 2004 FSH isoform composition of commercial gonadotrophin preparations: a neglected aspect? Reproductive BioMedicine Online 9, 231-236.
5. Arce J 2006 Impact of hCG levels in the mid-follicular phase during treatment with highly purified menotrophin on embryo quality and outcome in IVF cycles. Human Reproduction 21, i141.
6. Balasch J, Peñarrubia J, Fábregues F et al. 2003 Ovarian responses to recombinant FSH or BMG in normogonadotrophic women following pituitary desensitization by a depot GnRH agonist for assisted reproduction. Reproductive BioMedicine Online 7, 35-42.
7. Chalmers I 1993 The Cochrane collaboration: preparing, maintaining, and disseminating systematic reviews of the effects of health care. Annals of the New York Academy of Sciences 703, 156-163; discussion 163-155.
8. Cook RJ, Sackett DL 1995 The number needed to treat: a clinically useful measure of treatment effect. British Medical Journal 310, 452-454.
9. Coomarasamy A, Afnan M, Cheema D et al. 2008 Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis. Human Reproduction 23, 310-315.
10. de Koning CH, Benjamins T, Harms P et al. 2006 The distribution of FSH receptor isoforms is related to basal FSH levels in subfertile women with normal menstrual cycles. Human Reproduction 21, 443-446.
11. Dickey RP, Sartor BM, Pyrzak R 2004 What is the most relevant standard of success in assisted reproduction?: no single outcome measure is satisfactory when evaluating success in assisted reproduction; both twin births and singleton births should be counted as successes. Human Reproduction 19, 783-787.
12. Egger M, Smith GD 1997 Meta-analysis. Potentials and promise. British Medical Journal 315, 1371-1374.
13. European and Israeli Study Group 2002 Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in-vitro fertilization/intracytoplasmic sperm injection cycles: a randomized, comparative trial. Fertility and Sterility 78, 520-528.
14. Gordon UD, Harrison RF, Fawzy M, Hennelly B, Gordon AC 2001 A randomized prospective assessor-blind evaluation of luteinizing hormone dosage and in-vitro fertilization outcome. Fertility and Sterility 75, 324-431.
15. Guyatt G, Rennie D 2002 Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice, American Medical Association, Chicago.
16. Higgins JPT, Green S 2008 Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 (updated September 2008). Available at: www.cochrane-handbook.org [accessed 15 January 2009].
17. Ho JY, Chen MJ, Yi YC et al. 2003 The effect of preincubation period of oocytes on nuclear maturity, fertilization rate, embryo quality, and pregnancy outcome in IVF and ICSI. Journal of Assisted Reproduction and Genetics 20, 358-364.
18. Hompes PG, Broekmans FJ, Hoozemans DA et al. 2008 Effectiveness of highly purified human menopausal gonadotropin vs. recombinant follicle-stimulating hormone in first-cycle in-vitro fertilization-intracytoplasmic sperm injection patients. Fertility and Sterility 89, 1685-1693.
19. Isiklar A, Mercan R, Balaban B et al. 2004 Impact of oocyte pre-incubation time on fertilization, embryo quality and pregnancy rate after intracytoplasmic sperm injection. Reproductive BioMedicine Online 8, 682-686.
20. Jansen CA, van Os HC, Out HJ, Coelingh Bennink HJ 1998 A prospective randomized clinical trial comparing recombinant follicle stimulating hormone (Puregon) and human menopausal gonadotrophins (Humegon) in non-down-regulated in-vitro fertilization patients. Human Reproduction 13, 2995-2999.
21. Kilani Z, Dakkak A, Ghunaim S et al. 2003 A prospective, randomized, controlled dial comparing highly purified hMG with recombinant FSH in women undergoing ICSI: ovarian response and clinical outcomes. Human Reproduction 18, 1194-1199.
22. Kovalevsky G, Patrizio P 2005 High rates of embryo wastage with use of assisted reproductive technology: a look at the trends between 1995 and 2001 in the United States. Fertility and Sterility 84, 325-330.
23. Lin W, Bernard MP, Cao D et al. 2007 Follitropin receptors contain cryptic ligand binding sites. Molecular and Cellular Endocrinology 260-262, 83-92.
24. Magier S, van der Ven HH, Diedrich K, Krebs D 1990 Significance of cumulus oophorus in in-vitro fertilization and oocyte viability and fertility. Human Reproduction 5, 847-852.
25. Ng EH, Lau EY, Yeung WS, Ho PC 2001 HMG is as good as recombinant human FSH in terms of oocyte and embryo quality: a prospective randomized trial. Human Reproduction 16, 319-325.
26. Patrizio P, Bianchi V, Lalioti MD et al. 2007 High rate of biological loss in assisted reproduction: it is in the seed, not in the soil. Reproductive BioMedicine Online 14, 92-95.
27. Perez Mayorga M, Gromoll J, Behre RM et al. 2000 Ovarian response to follicle-stimulating hormone (FSH) stimulation depends on the FSH receptor genotype. Journal of Clinical Endocrinology and Metabolism 85, 3365-3369.
28. Platteau P, Andersen AN, Loft A et al. 2008 Highly purified HMG versus recombinant FSH for ovarian stimulation in IVF cycles. Reproductive BioMedicine Online 17, 190-198.
29. Platteau P, Smitz J, Albano C et al. 2004 Exogenous luteinizing hormone activity may influence the treatment outcome in in-vitro fertilization but not in intracytoplasmic sperm injection cycles. Fertility and Sterility 81, 1401-1404.
30. Rashidi BH, Sarvi F, Tehrani ES et al. 2005 The effect of HMG and recombinant human FSH on oocyte quality: a randomized single-blind clinical trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology 120, 190-194.
31. Rienzi L, Ubaldi F, Anniballo R et al. 1998 Preincubation of human oocytes may improve fertilization and embryo quality after intracytoplasmic sperm injection. Human Reproduction 13, 1014-1019.
32. Smitz J, Andersen AN, Devroey P, Arce JC 2007 Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinant FSH in IVF patients. Human Reproduction 22, 676-687.
33. Stewart LA, Clarke MJ 1995 Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group. Statistics in Medicine 14, 2057-2079.
34. Van Wely M, Westergaard LG, Bossuyt PM, Van der Veen F 2003 Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles. Cochrane Database of Systematic Reviews CD003973.
35. Westergaard LG, Erb K, Laursen SB et al. 2001 Human menopausal gonadotropin versus recombinant follicle-stimulating hormone in normogonadotropic women down-regulated with a gonadotropin-releasing hormoneagonist who were undergoing in vitro fertilization and intracytoplasmic sperminjection: a prospective randomized study. Fertility and Sterility 76, 543-549.
36. Wolfenson C, Groisman J, Couto AS et al. 2005 Batch-to-batch consistency of human-derived gonadotrophin preparations compared with recombinant preparations. Reproductive BioMedicine Online 10, 442-454.